---
title: Windward Bio Targets $175 Million IPO With a Bet on Twice-Yearly Treatments
description: A $50 million Sanofi investment adds backing as the Swiss biotech advances long-acting antibodies for asthma, COPD and inflammatory skin disease.
image: https://blog.ipoprophet.com/hubfs/Windward%20Bio%20Thumbnail.jpg
---

[Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments#main-content)

[![IPO\_PROPHET\_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com)

- [Login](https://app.ipoprophet.com/login)

Open main navigation

Close main navigation

- [Login](https://app.ipoprophet.com/login)

[Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4)

[Go Back to Home](http://www.ipoprophet.com/)

[Go Back to Blog](http://www.ipoprophet.com/blog)

 Nov 9, 2026, 4:56:46 PM

# Windward Bio Targets $175 Million IPO With a Bet on Twice-Yearly Treatments

![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman)

Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments)

![Wiinward Bio Logo](https://blog.ipoprophet.com/hs-fs/hubfs/Wiinward%20Bio%20Logo.png?width=540&height=108&name=Wiinward%20Bio%20Logo.png)

**Windward Bio Group AG (proposed Nasdaq: WWB)** plans to offer **10.29 million shares at $16–$18**, raising approximately **$175 million at the $17 midpoint**. The offering and concurrent private placement imply a basic market capitalization of approximately **$987 million**, excluding pre-funded warrants and other equity awards. **Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank** are underwriting the deal.

### The Business: Making Treatment Last Longer

Windward is developing antibody medicines designed to control inflammatory disease with fewer injections. Its lead candidate, **WIN378**, blocks thymic stromal lymphopoietin, or **TSLP**, an upstream driver of inflammation. The company is pursuing twice-yearly dosing in asthma and evaluating the drug in chronic obstructive pulmonary disease, or COPD.

For investors, the proposition is easy to understand: a medicine that maintains disease control while reducing treatment frequency could offer meaningful convenience for patients and physicians.

The harder question is whether that convenience comes with competitive efficacy and a dependable safety profile. Less frequent dosing becomes commercially valuable only if the medicine delivers the outcomes physicians need.

![Windward Pipeline](https://blog.ipoprophet.com/hs-fs/hubfs/Windward%20Pipeline.jpg?width=856&height=328&name=Windward%20Pipeline.jpg)

WIN027 adds a second approach by targeting two inflammatory pathways simultaneously. That expands the potential opportunity, but investors should evaluate it separately from WIN378: evidence supporting one molecule does not establish that another will succeed.

### Encouraging Early Data, With Larger Tests Ahead

Windward’s September announcement described an interim WIN378 analysis involving the first **98 patients** in the Phase 2 portion of POLARIS-1. The company reported sustained improvements in lung function and inflammatory biomarkers through week 24, supporting its twice-yearly dosing strategy.

Those findings provide a reason to advance development. The pivotal investment test is whether larger studies demonstrate durable reductions in asthma exacerbations alongside an acceptable safety profile.

Investors should also distinguish an interim analysis from the forthcoming primary results. Each adds evidence, but they carry different weight when assessing the likelihood of eventual approval.

![Windward Bio Financial placard](https://blog.ipoprophet.com/hs-fs/hubfs/Windward%20Bio%20Financial%20placard.jpg?width=725&height=480&name=Windward%20Bio%20Financial%20placard.jpg)

First-half research spending more than doubled year over year. For a development-stage biotech, the key question is what that spending accomplishes: trial enrollment, useful data and progress toward regulatory submissions.

### Sanofi’s Investment and the Funding Position

Sanofi has committed **$50 million** through common shares and pre-funded warrants alongside the IPO. Combined gross proceeds would be approximately **$225 million** at the midpoint.

Sanofi’s participation strengthens the financing story. It should be viewed as an investment commitment, however, rather than proof of clinical success or a promise of an acquisition.

Windward reported **$207.3 million** in cash, cash equivalents and marketable securities at June 30, 2026. Management expects existing resources plus the financing to support operations into **the first half of 2029**.

That projected runway makes trial execution especially important. Investors should monitor whether spending and enrollment remain aligned with the milestones the financing is intended to reach.

### IPO Prophet Perspective

Windward offers a clear clinical thesis: extend the duration of antibody treatment while preserving strong disease control.

Our focus would be on three questions:

- **Does efficacy hold up across the full dosing interval?**
- **Do larger studies confirm the early findings?**
- **Can the company reach pivotal readouts without materially weakening its funding position?**

At roughly a **$1 billion valuation**, investors are paying for substantial future clinical progress. The upcoming data will determine whether Windward earns greater confidence in that opportunity.

 

 

 

[IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Windward Bio](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/windward-bio)

[linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet)

---

[![IPO\_PROPHET\_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com)

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.

Copyright © 2025

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Eric Friedman",
    "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman"
  },
  "dateModified" : "2026-11-09T21:56:46.408Z",
  "datePublished" : "2026-11-09T21:56:46.000Z",
  "headline" : "Windward Bio Targets $175 Million IPO With a Bet on Twice-Yearly Treatments",
  "image" : [ "https://blog.ipoprophet.com/hubfs/Windward%20Bio%20Thumbnail.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/windward-bio-targets-175-million-ipo-with-a-bet-on-twice-yearly-treatments",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png"
    },
    "name" : "ipoprophet.com"
  }
}
```